Personalizing HOXB13 gene in prostate cancer

Background: Transcription of HOX family gene begins from embryonic development and is highly expressed in adults that is exclusive to the rectum, distal colon, and prostate.Methods: the data were collected from the PubMed database; considering articles from 2012 to 2018. Filters such as prostate cancer, personalized medicine, gene therapy, and HOXB13 are applied. The study is designed in PICO framework; problem as high prevalence and mortality, intervention as personalizing the treatment by checking HOXB13 in patients’ genome, comparison of standard therapy and personalized therapy, outcome according to the previous studies. PRISMA is used as checklist. The priority in data selection was reviews of meta-analysis and RCTs Findings: According to 28 articles, G84E variant of HOXB13 is associated with increased risk (up to 4.5 times) of prostate cancer. The mutation is more common in early-onset, familial prostate cancer (3.1%) than in those with late-onset, non-familial prostate cancer (0.6%). CONCLUSION: Gene mutations such as HOXB13 participate in the occurrence of prostate cancer. To personalize the treatment, increasing response to treatment, and therapy-related adverse effects we recommend to use HOXB13 gene therapy as the treatment along with current therapies.

کلیدواژه ها:

prostate cancer ، HOXB13 ، personalized therapy ، gene therapy